BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geh J. The use of chemoradiotherapy in oesophageal cancer. European Journal of Cancer 2002;38:300-13. [DOI: 10.1016/s0959-8049(01)00353-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, Thomas RJ. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:770-8. [PMID: 16550384 DOI: 10.1007/s00259-005-0040-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
2 Gemici C. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2007;109:1448-9; author reply 1449. [PMID: 17328063 DOI: 10.1002/cncr.22514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Simoens C, Korst AE, De Pooter CM, Lambrechts HA, Pattyn GG, Faircloth GT, Lardon F, Vermorken JB. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 2003;89:2305-11. [PMID: 14676811 DOI: 10.1038/sj.bjc.6601431] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
4 Simoens C, Lardon F, Pauwels B, De Pooter CM, Lambrechts HA, Pattyn GG, Breillout F, Vermorken JB. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 2008;8:65. [PMID: 18312675 DOI: 10.1186/1471-2407-8-65] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
5 Zingg U, Divalentino D, McQuinn A, Mardzuki A, Thompson SK, Karapetis CS, Watson DI. Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer. Clin Exp Gastroenterol 2009;2:75-83. [PMID: 21694830 DOI: 10.2147/ceg.s6273] [Reference Citation Analysis]
6 Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, Igaki H, Ito Y, Hoshino S, Tachibana S. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104:1045-1051. [PMID: 23648090 DOI: 10.1111/cas.12187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
7 Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95:705-709. [PMID: 16967056 DOI: 10.1038/sj.bjc.6603328] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]